Isatuximab - Immunogen/Sanofi

Drug Profile

Isatuximab - Immunogen/Sanofi

Alternative Names: Anti-CD38 monoclonal antibody - Sanofi; hu38SB19; SAR-650984

Latest Information Update: 08 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ImmunoGen
  • Developer Huntsman Cancer Institute; Sanofi
  • Class Antibodies; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD38 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Multiple myeloma
  • Phase II T cell lymphoma
  • Phase I/II Non-small cell lung cancer; Prostate cancer; Solid tumours
  • Discontinued Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 31 Jul 2018 Sanofi and University of Heidelberg Medical Center plans a phase III trial for Multiple myeloma (First-line therapy, Newly diagnosed, Combination therapy) (SCT eligible patients) in September 2018 (NCT03617731)
  • 16 Jul 2018 Phase-I/II clinical trials in Solid tumours (Inoperable/Unresectable, Monotherapy, Second-line therapy or greater, Refractory metastatic disease, Recurrent) in Belgium, Netherlands (IV) (EudraCT2018-000390-67)
  • 16 Jul 2018 Phase-I/II clinical trials in Solid tumours (Inoperable/Unresectable, Recurrent, Refractory metastatic disease, Combination therapy, Second-line therapy or greater) in Belgium, Netherlands (IV) (EudraCT2018-000390-67)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top